ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Pediatric Cancers

Pediatric Cancers

A study showed that testing pediatric brain tumors for genetic abnormalities is feasible and could play a role in guiding patients’ treatment.

Presentation with musculoskeletal manifestations as the only symptom in pediatric B-cell acute lymphoblastic leukemia was significantly associated with diagnostic delay. However, this delay did not affect patient prognosis.

The use of minimal residual disease provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia than did morphology.

The antioxidant sodium thiosulfate protects children and adolescents against cisplatin-induced hearing loss without any added serious adverse effects, according to a randomized study.

Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.

In this interview we discuss updates, challenges, and contributing factors associated with pediatric brain cancers.

Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in a recently published phase I/II study.

Pages

Subscribe to Pediatric Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.